Published in Clin Ther on August 01, 2004
The FGF/FGFR axis as a therapeutic target in breast cancer. Expert Rev Endocrinol Metab (2013) 0.77
Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching. J Cancer Res Clin Oncol (2007) 0.75
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res (2006) 4.95
Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol (2005) 3.49
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol (2013) 3.24
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol (2006) 2.23
Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol (2006) 1.70
Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail (2013) 1.70
The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat (2008) 1.68
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol (2009) 1.67
Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol (2012) 1.65
Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res (2004) 1.58
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg (2009) 1.46
Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. Clin Cancer Res (2006) 1.45
A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res (2009) 1.19
Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy. Int J Radiat Oncol Biol Phys (2012) 1.06
Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. Mol Oncol (2013) 1.02
Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res (2010) 0.96
Primary extraosseous ewing sarcoma of the kidney with level III inferior vena cava thrombus. Clin Genitourin Cancer (2009) 0.96
Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry. Mod Pathol (2012) 0.96
Primary Ewing's sarcoma of the ethmoid sinus with intracranial and orbital extension: case report and literature review. Am J Otolaryngol (2013) 0.95
Initial evaluation of quality indicators for psychosocial care of adults with cancer. Cancer Control (2009) 0.93
Phase 1 trial of Anvirzel in patients with refractory solid tumors. Invest New Drugs (2006) 0.92
HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma. Oncotarget (2013) 0.89
Automated quantitative RNA in situ hybridization for resolution of equivocal and heterogeneous ERBB2 (HER2) status in invasive breast carcinoma. J Mol Diagn (2013) 0.87
Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer. Breast Cancer Res Treat (2011) 0.85
A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications. Breast Cancer Res (2012) 0.84
Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat (2013) 0.81
Metronomic therapy for breast cancer. Curr Oncol Rep (2004) 0.81
Incorporating the Oncotype DX breast cancer assay into community practice: an expert Q&A and case study sampling. Clin Adv Hematol Oncol (2008) 0.78
Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer. Invest New Drugs (2002) 0.78
Images in clinical medicine. Bone destruction and regeneration in a patient with breast cancer. N Engl J Med (2008) 0.78
The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence. BMC Cancer (2010) 0.77
HER-2 amplification in tubular carcinoma of the breast. Am J Clin Pathol (2006) 0.77
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies. Cancer (2003) 0.77
Is single-agent chemotherapy acceptable in platinum-sensitive relapsed ovarian cancer? J Clin Oncol (2008) 0.75
Docetaxel as monotherapy in the treatment of advanced non-small-cell lung cancer in elderly patients. J Clin Oncol (2007) 0.75
S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. Am J Clin Oncol (2010) 0.75
HER2 status in bilateral breast cancer. Int J Fertil Womens Med (2007) 0.75
Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma. Invest New Drugs (2004) 0.75
Sorting through the recent controversies in breast cancer screening. Cleve Clin J Med (2010) 0.75
Unusual macular degeneration following breast cancer. Acta Ophthalmol Scand (2007) 0.75
Incidence of advanced symptomatic disease as primary endpoint in screening and prevention trials. AJR Am J Roentgenol (2007) 0.75
Incorporating the Oncotype DX breast cancer assay into community practice: An expert Q & A and case study sampling. Clin Adv Hematol Oncol (2008) 0.75
LATE-ONSET CHOROIDAL METASTASIS FROM BREAST CANCER. Retin Cases Brief Rep (2016) 0.75
Male breast carcinoma metastatic to the choroid: report of 3 cases and review of the literature. Eur J Ophthalmol (2011) 0.75